Ariel Pharmaceuticals, Inc. is a private specialty pharmaceutical company focused on development and commercialization of products for major unmet medical needs. Ariel’s business model is based on significant reduction of shareholder risk and short time to value inflection. We achieve this by in-licensing drugs that are already in human testing for clinical indications that have short development timelines, well-defined endpoints for efficacy, and established mechanism-of-action to ensure predictability and cost efficiency.
We are currently developing two drugs intended to meet unmet medical needs in migraine and osteoarthritis. The Company believes our licensed products are first-in-class, revolutionary therapeutic approaches with clinical indications that have significant market opportunity and limited competition.